AZ inks clot-fighter deal in India; NSCLC meds forecast to hit $7.9B by 2020; Adherence lags in heart attack patients;

> AstraZeneca ($AZN) continued its quest to build sales for its clot-fighting drug Brilinta (ticagrelor), tapping Sun Pharmaceutical to market the med in India under a new brand name, Axcer. Report

> The market for non-small cell lung cancer treatments is set to grow to $7.9 billion by 2020 as new meds Opdivo, from Bristol-Myers Squibb ($BMY), and Keytruda, from Pfizer ($PFE), win new indications and rack up sales gains, GBI Research says. Report

> Many patients who survive a heart attack don't take prescribed meds as directed afterward. Report

> Shire ($SHPG) won European approval for its constipation drug Resolor for men with chronic constipation; it's already approved for women. Report

> Sprout Pharmaceuticals' third run at FDA approval for its women's libido drug flibanserin hit a snag Tuesday with agency reviewers' reporting continued concerns that its risks outweigh its benefits. Report

> Roche ($RHHBY) remains the world's biggest seller of cancer drugs, but growth in its portfolio is slowing. Report

> Merck's ($MRK) combination cholesterol drug Liptruzet, which marries its Zetia drug with the active ingredient in Pfizer's Lipitor, hit the FDA shortage list after the company decided to withdraw the product. Report

And Finally... High-profile investors racked up gains this week on news out of the American Society of Clinical Oncology meeting. Report

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.